Company profile
AXIM Biotechnologies, Inc.
OTC: AXIM · Healthcare · Biotechnology
#1089 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
——FH —DQ 48GM —SS 37
v0.1 · 25/100 weight · pillars only
↑ revenue growth (YoY), disclosure history · ↓ net margin, operating margin
Methodology →Revenue TTM
$392.0k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$8.1M
Employees
7
as of 2026-08-25
Market cap
$1.4M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$39.5k$39.5k2023
Net income-$8.1M-$8.1M2023
Operating income-$2.8M-$2.8M2023
Total assets$4.1M$4.1M2023
Liabilities$11.8M$11.8M2023
Equity-$7.7M-$7.7M2023
Revenue trend
FY2016 – FY2023 · USD
FY16
FY17
FY18
FY19
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is AXIM Biotechnologies, Inc.’s revenue?
AXIM Biotechnologies, Inc. booked $39.5k in FY2023 revenue, growing 345% year over year — faster than 92% of Healthcare companies we track, at a -20395.0% net margin.
Peers · Healthcare
Millennium Sustainable Ventures Corp.——Altimmune, Inc.55CNeonc Technologies Holdings, Inc.10DUPD Holding Corp.——AREV Life Sciences Global Corp——Oragenics, Inc.46DNeighbors
San Diego →Key facts
CEOCatalina Valencia
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeOTC: AXIM
Employees7
IPO date2014-09-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.